Unbiased News Awaits.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Artificial Intelligence
Social Media
Donald Trump
Money
European Union
Vladimir Putin
Stock Markets
Baseball
Volodymyr Zelenskyy
Education
Apple
Published • loading... • Updated

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its ...

Summary by Hastings Tribune
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%

1 Articles

All
Left
Center
1
Right
Hastings TribuneHastings Tribune
Center

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its ...

Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Monday, May 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Hastings, Nebraska

Hastings, Nebraska

News
For You
SearchBlindspotLocal